Danicopan: all 26 studies that test it

Page 1 of 1. Open to participants first (1), then studies with results posted, then the rest; newest registration first within each.

• Study of Danicopan as Add-on Treatment to Ravulizumab or Eculizumab in Pediatric Participants With PNH Who Have Clinically Significant Extravascular HemolysisRecruitingNCT06449001Phase 3
• A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular DegenerationTerminatedNCT05019521Phase 2Results posted
• ACTIV-5 / Big Effect Trial (BET-C) for the Treatment of COVID-19CompletedNCT04988035Phase 2Results posted
• Danicopan as Add-on Therapy to a C5 Inhibitor in Paroxysmal Nocturnal Hemoglobinuria (PNH) Participants Who Have Clinically Evident Extravascular Hemolysis (EVH)(ALPHA)CompletedNCT04469465Phase 3Results posted
• Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to EculizumabCompletedNCT03472885Phase 2Results posted
• A Proof of Concept Study for a 12 Month Treatment in Patients With C3G or IC-MPGN Treated With ACH-0144471TerminatedNCT03459443Phase 2Results posted
• A Proof-of-Concept Study of Danicopan for 6 Months of Treatment in Participants With C3 Glomerulopathy (C3G)CompletedNCT03369236Phase 2Results posted
• A Long-Term Treatment Study of ACH-0144471 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT03181633Phase 2Results posted
• A Proof-of-Mechanism Study to Determine the Effect of Danicopan on C3 Levels in Participants With C3G or IC-MPGNCompletedNCT03124368Phase 2Results posted
• Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)CompletedNCT03053102Phase 2Results posted
• Potential Drug Interaction Between ALXN2040 and RosuvastatinCompletedNCT05708573Phase 1
• A Long-term Safety and Efficacy Study of Danicopan as an Add-on Therapy to Complement Component 5 Inhibitor (C5i) in Participants With PNHActive, not recruitingNCT05389449Phase 3
• A Study of the Drug Interactions Between Danicopan and Cyclosporine, Tacrolimus, Antacids, and Omeprazole in Healthy AdultsCompletedNCT05109390Phase 1
• A Study of the Cardiac Effects of Danicopan in Healthy AdultsCompletedNCT05016206Phase 1
• Study of Different Forms of Danicopan (Tablet, Softgel Capsule, Liquid-filled Capsule) in Healthy ParticipantsCompletedNCT04940559Phase 1
• Study of Danicopan in Participants With Normal Kidney Function and Participants With Kidney DysfunctionCompletedNCT04935294Phase 1
• Study of Multiple Doses of Danicopan in Healthy ParticipantsCompletedNCT04889690Phase 1
• Study of a Single Dose of Danicopan in Healthy ParticipantsCompletedNCT04889677Phase 1
• Study of Radiolabeled Danicopan in Healthy Male ParticipantsCompletedNCT04889391Phase 1
• A Drug Interaction Study of DanicopanCompletedNCT04709094Phase 1
• Study of the Metabolism of Danicopan in Healthy AdultsCompletedNCT04609696Phase 1
• A Study of the Effects of Food and Age on DanicopanCompletedNCT04551599Phase 1
• Study of Danicopan in Participants of Japanese DescentCompletedNCT04451434Phase 1
• Study of Danicopan in Participants With Hepatic ImpairmentCompletedNCT03555539Phase 1
• A Study of Modified Release Formulations of Danicopan in Healthy Adult ParticipantsCompletedNCT03384186Phase 1
• A Drug Interaction Study Between Danicopan and Midazolam, Fexofenadine, and Mycophenolate Mofetil in Healthy ParticipantsCompletedNCT03108274Phase 1

← Danicopan overview